Apellis Pharmaceuticals Inc (APLS)

$47.51 0.52 (1.08%)

16:00 EDT APLS Stock Quote Delayed 30 Minutes

Apellis Layoffs 2023: What to Know About the Latest APLS Job Cuts

By William White, InvestorPlace Writer Aug 29, 2023

Apellis Pharmaceuticals (APLS) layoffs are a hot topic on Tuesday as the commercial-stage biopharmaceutical company prepares for job cuts.

3 Very Oversold Pharma Stocks to Buy Right Now

Why Is Apellis Pharmaceuticals (APLS) Stock Up 23% Today?

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

More Articles

Volume:

Previous Close -

Market Cap 5.53B

PE Ratio -30.46

EPS -1.56

Volume (Avg. Vol.) 1.95M

Day's Range $46.40 - $48.83

52-Week Range $19.83 - $94.75

Dividend & Yield N/A (N/A)

APLS Stock Predictions, Articles, and Apellis Pharmaceuticals Inc News

From InvestorPlace
From the Web

3 Sorry Pharma Stocks to Sell in August Before It’s Too Late

By Tyrik Torres, InvestorPlace Contributor Aug 22, 2023

Factors in the marketplace caused these companies to underperform, making them some of the top pharma stocks to sell.

Want to Get Rich? 3 Game-Changing Biotech Stocks to Buy Right Now

By Ian Cooper, InvestorPlace Contributor Aug 21, 2023

Biotech stocks may offer some of the most explosive opportunities on the market. Here are three with major catalysts nearing.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

By William White, InvestorPlace Writer Jul 17, 2023

It's time to start off the trading week with a breakdown of all the biggest pre-market stock movers worth watching on Monday!

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

By William White, InvestorPlace Writer Feb 21, 2023

It's time to start another day of trading with a breakdown of the biggest pre-market stock movers traders need to know about for Tuesday!

APLS Stock: The Trial Results That Have Apellis Pharmaceuticals Plunging Today

By Chris MacDonald, InvestorPlace Contributor Sep 10, 2021

Here's why investors are in full selloff mode today with APLS stock on Apellis Pharmaceuticals' latest clinical trial results.

ISEE Stock: Why Rival Eye Drug Developer’s Disappointment Is a Boon to IVERIC bio

By William White, InvestorPlace Writer Sep 10, 2021

IVERIC bio (ISEE) stock is rocketing higher on Friday and there's a couple of catalysts behind the shares' positive movement today.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

By William White, InvestorPlace Writer Sep 10, 2021

We're back at it again with one last day of trading this week and we're kicking it off with Friday's biggest pre-market stock movers.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

By William White, InvestorPlace Writer May 17, 2021

Good morning! Let's get ready for another exciting week of trading with a look at the biggest pre-market stock movers for Monday.

Apellis is Outperforming the Pharmaceutical Sector

By Ken Trester Apr 24, 2020

This week I want to take a bullish position in the underperforming pharmaceutical sector with Apellis Pharmaceuticals, Inc. (NASDAQ:APLS).

The 5 Stocks Most Sold By Insiders This Year

From MarketBeat Apr 16, 2024

Insiders are selling these 5 stocks increased as their markets advanced, and gains may be capped. Long-term outlooks are positive for growth and share prices.

Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments

From MarketBeat Mar 6, 2024

Beam Therapeutics stock is rising as the company begins to receive significant money from the multiple licensing deals it has in place

Beam stock jumps as Eli Lilly deal brings Q4 beat (NASDAQ:BEAM)

From Seeking Alpha Feb 27, 2024

Beam Therapeutics (BEAM) stock gains as the company reports profits in Q4 after boosting revenue thanks to a collaboration deal with Eli Lilly (LLY). Read more here.

Apellis Pharmaceuticals GAAP EPS of -$0.73 misses by $0.04, revenue of $146.4M beats by $2.81M (NASDAQ:APLS)

From Seeking Alpha Feb 27, 2024

Apellis Pharmaceuticals reports Q4 2023 financial results: GAAP EPS misses expectations by $0.04, but revenue beats estimates by $2.81M.

Why Shares of Apellis Pharmaceuticals Were Down Wednesday

From The Motley Fool Sep 27, 2023

A short-seller report sent the stock tumbling.

Apellis stock falls as EU rejects eye therapy (NASDAQ:APLS)

From Seeking Alpha Jan 26, 2024

Apellis Pharmaceuticals (APLS) stck trades lower as the European Medicines Agency (EMA) does not endorse its eye disease therapy, pegcetacoplan. Read more here.

ADVERTISEMENT